THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN, IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
THE INFORMATION COMMUNICATED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
11 December 2020
ReNeuron Group plc
("ReNeuron", the "Group" or the "Company")
Result of Open Offer
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has conditionally raised total gross proceeds of approximately £2.5 million through the Open Offer announced on 23 November 2020, representing the full amount proposed under the Open Offer.
Accordingly, the Company has conditionally raised total gross proceeds of approximately £17.5 million (before expenses) in aggregate by way of the Placing and Subscription (which were also announced on 23 November 2020) and the Open Offer.
Applications have been made to the London Stock Exchange for the admission of 24,970,381 New Ordinary Shares to trading on AIM (the "Admission"). This comprises (i) 5,186,854 EIS/VCT Placing Shares; (ii) 14,734,575 General Placing Shares; (iii) 1,507,139 Subscription Shares; and (iv) 3,541,813 Open Offer Shares. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares.
Admission of the EIS/VCT Placing Shares is expected to occur on 14 December 2020 and on 15 December 2020 for the General Placing Shares, Subscription Shares and Open Offer Shares, subject to Shareholders passing the relevant Resolutions at the General Meeting to be held today.
Olav Hellebø, Chief Executive Officer of ReNeuron, commented: "Our thanks go to the shareholders that participated in this Open Offer, which has resulted in a total of £17.5 million gross being raised in this significantly over-subscribed fundraising. We are at a very exciting time in the development of the Company. During the months ahead, we will continue to advance our pioneering Phase 2a clinical study in retinitis pigmentosa, including the opening of a UK trial site, and to deliver further clinical data. We will also pursue licensing deals from our exosome platform and from our induced pluripotent stem cell (iPSC) technology with the overall objective of creating significant value in the year ahead."
Analyst conference call and webcast
A conference call for analysts will be held at 10.00 a.m. on 6 January 2021 to discuss the Company's recent half year results, the fundraising and outlook for the year ahead. Analysts who require dial-in details please contact Buchanan at firstname.lastname@example.org.
A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 6 January 2021 at this link:
The recorded webcast will also be made available at the investor centre of ReNeuron's website, http://www.reneuron.com/investors/investor-centre/.
Unless otherwise stated, the capitalised terms used in this announcement have the same meanings as in the announcement of the Transaction made by the Company on 23 November 2020.
+44 (0) 20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (Media/Investor relations)
+44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited (NOMAD, Broker and Sole Bookrunner)
+44 (0) 20 7710 7600
Ben Maddison, Stewart Wallace
For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, the person responsible for arranging for the release of this announcement on behalf of the Company is Olav Hellebø, Chief Executive Officer.
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
This announcement may contain and the Company may make verbal statements containing "forward-looking statements" with respect to certain of the Company's plans and its current goals and expectations relating to its future financial condition, performance, strategic initiatives, objectives and results. Forward-looking statements sometimes use words such as "aim", "anticipate", "target", "expect", "estimate", "intend", "plan", "goal", "believe", "seek", "may", "could", "outlook" or other words of similar meaning. By their nature, all forward-looking statements involve risk and uncertainty because they relate to future events and circumstances which are beyond the control of the Company. As a result, the actual future financial condition, performance and results of the Company may differ materially from the plans, goals and expectations set forth in any forward-looking statements. Any forward-looking statements made in this announcement by or on behalf of the Company speak only as of the date they are made. The information contained in this announcement is subject to change without notice and except as required by applicable law or regulation, the Company expressly disclaims any obligation or undertaking to publish any updates or revisions to any forward-looking statements contained in this announcement to reflect any changes in the Company's expectations with regard thereto or any changes in events, conditions or circumstances on which any such statements are based.
Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.
Stifel Nicolaus Europe Limited ("Stifel"), which is authorised and regulated in the United Kingdom by the FCA, is acting for the Company and no-one else in connection with the transactions and arrangements described in this announcement and will not regard any other person (whether or not a recipient of this announcement) as a client in relation to the transactions and arrangements described in this announcement. Stifel is not responsible to anyone other than the Company for providing the protections afforded to clients of Stifel or for providing advice in connection with the contents of this announcement or the transactions and arrangements described herein.